Screener
BridgeBio Pharma BBIO EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from BridgeBio Pharma’s reported figures.
Based on trailing twelve months.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
FAQ
- What is BridgeBio Pharma's EBITDA margin?
- BridgeBio Pharma (BBIO) reported EBITDA margin of -89.6% in Q1 2026.
- How has BridgeBio Pharma's EBITDA margin changed year-over-year?
- BridgeBio Pharma's EBITDA margin increased by 83.5% year-over-year, from -543% to -89.6%.
- What is the long-term trend for BridgeBio Pharma's EBITDA margin?
- Over 4 years (2021 to 2025), BridgeBio Pharma's EBITDA margin has grown at a -40.4% compound annual growth rate (CAGR), from -818.7% to -103.2%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about BridgeBio Pharma's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude